8-K: Kodak Reports Q2 Loss, FDA Nod for Pharma Unit

Eastman Kodak Company reported a significant net loss and declining revenues for Q2 2025, alongside a crucial FDA registration for its Advanced Materials & Chemicals pharmaceutical manufacturing facility.

Summary

• Consolidated revenues for Q2 2025 were $263 million, a 1% decrease from $267 million in Q2 2024.
• GAAP net loss was $26 million in Q2 2025, a 200% decrease from net income of $26 million in Q2 2024.
• Gross profit decreased by 12% to $51 million in Q2 2025 from $58 million in Q2 2024, with gross profit percentage falling to 19% from 22%.
• Operational EBITDA was $9 million in Q2 2025, a 25% decrease from $12 million in Q2 2024.
• Cash balance at quarter-end was $155 million, a $46 million decrease from $201 million on December 31, 2024.
• Cash flow from operations decreased by $40 million from the prior-year period.
• The Advanced Materials & Chemicals (AM&C) group's cGMP pharmaceutical manufacturing facility is now registered with the FDA and certified to manufacture and sell regulated pharmaceutical products.
• The AM&C facility will begin manufacturing phosphate buffered saline (PBS) for laboratory use, with future plans for injectable IV saline.
• The company is assessing the potential impact of new tariffs, noting its commitment to U.S. manufacturing.
• The termination of the U.S. Kodak Retirement Income Plan (KRIP) and subsequent reversion of excess funds to pay down debt is progressing, with a clear understanding expected by August 15, 2025, and completion anticipated by December 2025.
• A disclosure regarding substantial doubt about the company's ability to continue as a going concern was included in the second quarter 2025 Form 10-Q filing.

Sentiment

Score: 3

Explanation: The financial results are significantly negative, with a substantial net loss, declining revenues, and a notable decrease in cash. The explicit 'going concern' warning is a major red flag. While the FDA registration for the AM&C segment is a positive strategic development, it is overshadowed by the overall poor financial performance and liquidity concerns.

Positives

• The Advanced Materials & Chemicals (AM&C) group's cGMP pharmaceutical manufacturing facility achieved FDA registration and certification, expanding its business into regulated pharmaceutical products.
• The AM&C segment showed revenue growth, increasing by $2 million to $75 million in Q2 2025 compared to Q2 2024.
• The company saw a significant improvement in its use of cash in Q2 2025 compared to Q1 2025, reducing the cash balance by $3 million in Q2.
• The ongoing process of terminating the Kodak Retirement Income Plan (KRIP) and reverting excess funds is expected to help reduce term debt.

Negatives

• Consolidated revenues decreased by 1% to $263 million in Q2 2025 compared to Q2 2024.
• The company reported a GAAP net loss of $26 million in Q2 2025, a 200% decline from a net income of $26 million in Q2 2024.
• Gross profit decreased by 12% to $51 million, and the gross profit percentage declined by 3 percentage points to 19%.
• Operational EBITDA decreased by 25% to $9 million in Q2 2025.
• The cash balance decreased by $46 million from December 31, 2024, to $155 million at June 30, 2025.
• Cash flow from operations decreased by $40 million from the prior-year period.
• The decrease in Operational EBITDA was primarily driven by lower volumes and higher aluminum and manufacturing costs.
• The company included a disclosure regarding substantial doubt about its ability to continue as a going concern.

Risks

• Ability to improve and sustain operating structure, cash flow, profitability, and other financial results.
• Ability to achieve strategic objectives, cash forecasts, financial projections, and projected growth.
• Ability to obtain additional or alternate financing, manage worldwide cash, and provide/facilitate customer financing.
• Uncertainty regarding the receipt of projected reversion proceeds from the liquidation of the Kodak Retirement Income Plan (KRIP) at the contemplated time.
• Ability to fund continued investments, capital needs, and collateral requirements, and to service its debt and Series B and C Preferred Stock.
• Changes in foreign currency exchange rates, commodity prices, interest rates, and tariff rates.
• Impact of the global economic environment, including inflationary pressures, geopolitical issues (e.g., war in Ukraine, conflicts involving Israel), changes in trade policies, and the ability to mitigate associated increased costs of raw materials, energy, labor, shipping, and production delays.
• Ability to effectively compete with large, well-financed industry participants or competitors with lower cost structures.
• Performance by third parties of their obligations to supply products, components, or services, and the ability to address supply chain disruptions and obtain raw materials from single or limited sources.
• Ability to comply with covenants in various credit facilities.
• Ability to effectively anticipate technology and industry trends (including AI) and develop/market new products and solutions.
• Ability to effect strategic transactions (investments, acquisitions, alliances, divestitures) and achieve their intended benefits.
• Ability to manage, defend, and resolve current and legacy claims without incurring material losses or business disruptions.
• Ability to discontinue, sell, or spin-off certain non-core businesses or operations, or otherwise monetize assets.
• Potential impact of force majeure events, cyberattacks, or other data security incidents or IT outages that could disrupt operations.

Future Outlook

The company plans to focus on serving customers, strengthening its balance sheet, and developing growth businesses for the balance of the year. It expects to have a clear understanding by August 15, 2025, on how to satisfy obligations to Kodak Retirement Income Plan participants and anticipates completing the reversion of excess funds by December 2025. For the second half of the year, the focus will be on reducing costs and converting investments into long-term growth. The company also plans to manufacture more sophisticated specialty products, such as injectable IV saline, in the future from its newly FDA-registered facility.

Management Comments

• Jim Continenza, Executive Chairman and CEO: "In the second quarter, Kodak continued to make progress against our long-term plan despite the challenges of an uncertain business environment. While tariffs did not have a material impact on our business in Q2, we are assessing the potential impact of new tariffs going forward. It's important to note that Kodak is committed to U.S. manufacturing... and our expectation is that tariffs instituted by the U.S. government are designed to protect American businesses like ours. I'm pleased to report that our AM&C group's cGMP pharmaceutical manufacturing facility is now registered with the FDA and certified to manufacture and sell regulated pharmaceutical products, expanding our current business in unregulated pharmaceutical products. For the balance of the year, we plan to focus on serving our customers, strengthening our balance sheet and developing growth businesses for our future."
• David Bullwinkle, CFO: "Revenue for the quarter was roughly flat year over year, which was in line with expectations, and we continued to see revenue growth in our AM&C business. In Q2 we saw a significant improvement in our use of cash compared with the first quarter, reducing our cash balance by $3 million to $155 million, compared with $201 million on December 31, 2024. The termination of our U.S. Kodak Retirement Income Plan and subsequent reversion of excess funds to pay down debt is progressing as planned. For the second half of the year, we will continue to focus on reducing costs today and converting our investments into long-term growth."

Industry Context

Kodak's results reflect ongoing challenges in its traditional Print segment, which continues to see declining revenues and profitability. However, the growth in the Advanced Materials & Chemicals (AM&C) segment, particularly with the FDA registration for pharmaceutical manufacturing, indicates a strategic pivot towards higher-growth, specialized markets. This move aligns with a broader industry trend among legacy manufacturing companies to diversify into advanced materials and life sciences to leverage existing chemical expertise and infrastructure, seeking new revenue streams beyond their mature core businesses. The mention of tariffs and U.S. manufacturing commitment also highlights the increasing focus on domestic production and supply chain resilience in the current geopolitical climate.

Comparison to Industry Standards

• NA

Legal Proceedings

• The company continues to manage, defend, and resolve a variety of current and legacy claims.

Stakeholder Impact

• Shareholders: Significant negative impact due to net loss, declining profitability, cash burn, and the going concern warning, which could lead to share price depreciation and increased investment risk.
• Creditors: Increased risk due to the going concern warning and the need to amend, extend, or refinance debt and preferred stock obligations.
• Employees: Potential impact from cost reduction efforts and ongoing operational efficiency improvements.
• Customers: Continued focus on serving customers, but potential long-term impact if financial instability affects product development or support.
• Suppliers: Potential impact from changes in working capital and the company's ability to manage costs and payables.

Next Steps

• Focus on serving customers, strengthening the balance sheet, and developing growth businesses for the balance of the year.
• Assess the potential impact of new tariffs going forward.
• Begin operation manufacturing phosphate buffered saline (PBS) for laboratory use at the newly FDA-registered facility.
• Create a bridge to manufacturing more sophisticated specialty products, such as injectable IV saline, in the future.
• Obtain a clear understanding by August 15, 2025, of how obligations to Kodak Retirement Income Plan participants will be satisfied.
• Complete the reversion of excess funds from the Kodak Retirement Income Plan by December 2025.
• Continue to focus on reducing costs and converting investments into long-term growth for the second half of the year.
• Amend, extend, or refinance remaining debt and preferred stock obligations.

Key Dates

Recommendation

The company reported a substantial net loss, significant declines in gross profit and EBITDA, and a notable reduction in its cash balance. Most critically, the filing includes an explicit 'going concern' warning, indicating substantial doubt about its ability to continue operations. While there's a positive strategic development with the FDA registration for the AM&C unit, the severe financial deterioration and the going concern risk far outweigh this positive, making the stock a high-risk investment with significant downside potential. The reliance on pension fund reversion for debt reduction, which is not deemed probable under GAAP, further exacerbates the risk profile.

Keywords

Kodak, KODK, Q2 2025 earnings, financial results, net loss, revenue, EBITDA, Advanced Materials & Chemicals, pharmaceutical manufacturing, FDA registration, going concern, pension plan, debt reduction, printing industry, specialty chemicals